News articles about Illumina (NASDAQ:ILMN) have been trending somewhat positive on Friday, according to Accern Sentiment Analysis. Accern rates the sentiment of media coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Illumina earned a media sentiment score of 0.16 on Accern’s scale. Accern also gave news articles about the life sciences company an impact score of 47.9623928127275 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.

Here are some of the headlines that may have effected Accern’s rankings:

Illumina (ILMN) traded down $4.79 during trading on Friday, reaching $225.24. The company’s stock had a trading volume of 972,083 shares, compared to its average volume of 956,698. The company has a debt-to-equity ratio of 0.41, a quick ratio of 3.73 and a current ratio of 4.22. The firm has a market cap of $32,890.00, a PE ratio of 66.16, a price-to-earnings-growth ratio of 3.74 and a beta of 0.74. Illumina has a 12-month low of $119.37 and a 12-month high of $230.72.

Illumina (NASDAQ:ILMN) last issued its earnings results on Tuesday, October 24th. The life sciences company reported $1.11 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.99 by $0.12. Illumina had a return on equity of 19.42% and a net margin of 30.34%. The business had revenue of $714.00 million during the quarter, compared to analysts’ expectations of $692.77 million. During the same period in the prior year, the firm posted $0.97 EPS. Illumina’s quarterly revenue was up 17.6% compared to the same quarter last year. sell-side analysts expect that Illumina will post 3.75 earnings per share for the current year.

ILMN has been the topic of a number of recent research reports. Leerink Swann restated an “outperform” rating and issued a $225.00 target price (up previously from $207.00) on shares of Illumina in a research note on Tuesday, September 12th. Piper Jaffray Companies restated an “overweight” rating and issued a $226.00 target price (up previously from $202.00) on shares of Illumina in a research note on Monday, October 9th. Citigroup boosted their target price on Illumina from $180.00 to $220.00 and gave the company a “neutral” rating in a research note on Wednesday, October 25th. Janney Montgomery Scott upgraded Illumina from a “sell” rating to a “neutral” rating in a research note on Monday, October 23rd. Finally, Zacks Investment Research downgraded Illumina from a “buy” rating to a “hold” rating in a research note on Tuesday, October 31st. Two equities research analysts have rated the stock with a sell rating, nine have issued a hold rating and thirteen have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average target price of $200.88.

In related news, Director Jay T. Flatley sold 20,000 shares of the stock in a transaction that occurred on Tuesday, September 26th. The stock was sold at an average price of $200.16, for a total transaction of $4,003,200.00. Following the sale, the director now directly owns 539,176 shares in the company, valued at approximately $107,921,468.16. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, SVP Oene Mark Van sold 9,729 shares of the stock in a transaction that occurred on Tuesday, September 12th. The stock was sold at an average price of $211.33, for a total value of $2,056,029.57. Following the sale, the senior vice president now owns 24,908 shares in the company, valued at $5,263,807.64. The disclosure for this sale can be found here. Over the last three months, insiders sold 161,360 shares of company stock valued at $33,599,137. 0.89% of the stock is currently owned by insiders.

WARNING: This piece was posted by Daily Political and is the property of of Daily Political. If you are reading this piece on another website, it was illegally copied and republished in violation of US & international copyright laws. The original version of this piece can be read at https://www.dailypolitical.com/2017/12/01/illumina-ilmn-getting-somewhat-positive-news-coverage-accern-reports.html.

Illumina Company Profile

Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.

Insider Buying and Selling by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with MarketBeat.com's FREE daily email newsletter.